Leibundgut K, Muff J, Hirt A, Mitschulat H, Nydegger U E, Lüthy A R, Tobler A, Wagner H P
Department of Pediatrics, University of Bern, Switzerland.
Transfus Sci. 1994 Mar;15(1):93-9. doi: 10.1016/0955-3886(94)90062-0.
In a single institution trial we carried out 35 peripheral blood stem cell harvesting procedures in 12 children with advanced malignancies to evaluate the procedure's safety and the collection efficiency of the Fresenius blood cell separator AS 104 in a pediatric population. Despite a significant mean decrease of 21% (+/-8%) in systolic blood pressure after starting the procedure, all children tolerated leukapheresis without any adverse reaction. After termination of leukapheresis there was a significant decrease of all determined hematological parameters, as compared with pre-harvest values. The mean mononuclear cell recovery was 64% (+/-26%), and in 25/35 (71%) harvesting procedures the minimum progenitor number required for safe autografting could be obtained by one single leukapheresis. We conclude that the Fresenius AS 104 blood cell separator provides a high cell yield and is a safe device for leukapheresis in pediatric patients.
在一项单机构试验中，我们对12名患有晚期恶性肿瘤的儿童进行了35次外周血干细胞采集程序，以评估该程序在儿科人群中的安全性以及费森尤斯血细胞分离机AS 104的采集效率。尽管在程序开始后收缩压平均显著下降了21%（±8%），但所有儿童均耐受白细胞单采术，未出现任何不良反应。与采集前的值相比，白细胞单采术结束后所有测定的血液学参数均显著下降。平均单个核细胞回收率为64%（±26%），在25/35（71%）的采集程序中，通过一次白细胞单采术即可获得安全自体移植所需的最低祖细胞数量。我们得出结论，费森尤斯AS 104血细胞分离机可提供高细胞产量，是儿科患者进行白细胞单采术的安全设备。
